[Adipocytokines: implications in the prognosis and drug treatment of cardiovascular diseases].
Adipocytokines, fat tissue derived factors with regulatory properties, are involved in the pathophysiology of atheromatous and metabolic illnesses such as: ischemic heart disease, insulin resistance, obesity, dyslipidemia and diabetes mellitus. Enlargement of visceral adipose tissue depots determines a worse evolution for those complaints. Drugs as angiotensin converting enzyme inhibitors (ACEI), thiazolidinediones (glitazones) or angiotensin-II receptor antagonists, generally associated with the adequate hypolipidemic (statins, fibrates) or antiobesity (orlistat, sibutramine, rimonabant) medication, would increase those adipocytokines with anti-inflammatory and insulin-sensitizing properties (i.e. adiponectin or visfatin), while reducing pro-inflammatory and thrombogenic cytokines (as leptin, tumor necrosis factor [TNF]-alpha, plasminogen activator inhibitor 1 [PAI-1]). Thus, these pharmacologic therapeutic approaches would have a beneficial effect in order to diminish morbidity-mortality and improve the prognosis of patients with said diseases, all of them related to high cardiovascular risk.
Iglesias-Osma
M C
MC
Departamento de Fisiología y Farmacología, Facultad de Medicina, Universidad de Salamanca, Salamanca, Spain. mcio@usal.es
Torres
M A
MA
García-Barrado
M J
MJ
Moratinos
J
J
D054392:Adipokines / Q000502:physiology*; D052242:Adiponectin / Q000502:physiology; D000273:Adipose Tissue / Q000502:physiology; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D011379:Prognosis; D012307:Risk Factors
D054392:Adipokines; D052242:Adiponectin